[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pan Xiangbin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":143},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,67,96,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100599660","phase-4-perioperative-intensive-statin-therapy-for-neuroprotection-in-tavrpistnt-100599660",false,"NCT07087379","Perioperative Intensive Statin Therapy for Neuroprotection in TAVR（PISTNT）","Perioperative Intensive Statin Therapy for Neuroprotection in Transcatheter Aortic Valve Replacement","PISTNT","Inclusion Criteria:\n\n* Patients aged ≥65-80 years with symptomatic severe aortic stenosis at the time of screening for enrollment;\n* It is planned to undergo transcatheter aortic valve replacement at a scheduled time;\n* Informed consent from the patient or the guardian;\n* American Society of Anesthesiologists (ASA) classification I-III;\n* Possess comprehensive reading, listening, and speaking abilities, and be able to cooperate in completing neuropsychological tests\n\nExclusion Criteria:\n\n* Impaired preoperative cognitive function, with a Montreal Cognitive Assessment score of ≤20;\n* Previous history of disabling stroke (modified Rankin Scale score ≥3) or carotid stenosis exceeding 70%, or severe stenosis of the subclavian artery or brachiocephalic trunk;\n* Preoperative baseline MRI indicated acute or subacute ischemic brain injury;\n* Have taken statins within the past month;\n* Renal failure (glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2);\n* Allergic to atorvastatin;\n* Contraindications to atorvastatin (active liver disease with unexplained persistent elevation of liver enzymes\u002Fhistory of muscle disease);\n* Patients with permanent pacemaker implantation or those who cannot undergo MRI due to claustrophobia;\n* Severe systemic disease with an expected life expectancy of less than 90 days;\n* There are any other medical or non-medical reasons, such as inability to comply with research procedures or follow-up, or plans to relocate during the study period, that the researcher deems unsuitable for the subject to participate in the study","ALL","65 Years","80 Years",{"count":21,"type":22},500,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Transcatheter aortic valve replacement (TAVR) has become the most anticipated treatment method in the cardiovascular field in recent years, experiencing rapid development. However, neurological complications related to the surgery, such as ischemic injury, stroke, transient ischemic attack, and postoperative delirium, remain the main causes of increased postoperative mortality. Currently, there are limited measures for neuroprotection during the perioperative period of TAVR, and controversy continues over the effectiveness of intraoperative cerebral device placement. Consequently, strategies for neuroprotection during TAVR require active exploration. Previous studies have shown that statins have pleiotropic effects. In addition to inhibiting cholesterol synthesis, it also exhibits anti-inflammatory, antioxidant, stress-reducing, and platelet aggregation-inhibiting properties, as well as potential neuroprotective effects. The efficacy and safety of intensive statin therapy during the perioperative period of percutaneous coronary intervention have been extensively examined, and its role in improving long-term prognosis has been recognised. Since coronary heart disease and aortic valve stenosis share similar pathophysiological mechanisms, the use of statins in valve replacement surgery has also demonstrated positive effects. Research indicates that preoperative high-intensity statin therapy can reduce the incidence of stroke or transient ischemic attack following valve replacement surgery. Additionally, evidence suggests that preoperative statin use can decrease the occurrence of postoperative delirium. However, no evidence exists on whether perioperative intensive statin therapy during TAVR can reduce cerebral ischaemic injury and provide neuroprotection. This study aims to conduct a prospective, randomised, double-blind, multicentre clinical trial to evaluate the neuroprotective effects of statin-enhanced therapy during the perioperative period of TAVR and to investigate whether it can reduce cerebral ischaemic injury after TAVR.",[28,29],"Aortic Stenosis","Cerebral Ischaemic Injury","NOT_YET_RECRUITING","2025-07-24",{"date":33,"type":34},"2025-07-28","ACTUAL",{"date":36,"type":22},"2025-10-01",{"date":38,"type":22},"2028-01-01",{"name":40,"class":41},"Pan Xiangbin","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100595254","echocardiography-guided-tavr-echo-tavr-100595254","NCT07030062","Echocardiography Guided TAVR (Echo TAVR)","Transcatheter Aortic Valve Replacement With Echocardiography Guidance","Inclusion Criteria:\n\n1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m\u002Fs, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2\u002Fm2);\n2. a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;\n3. chronic kidney disease and refuse to receive contrast agents or radiation exposure.\n\nExclusion Criteria:\n\nRequired hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.",{"count":50,"type":22},20,"1 Month","OBSERVATIONAL","Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.",[55,56],"Transcatheter Aortic Valve Replacemen","Echocardiography","RECRUITING","2025-06-12",{"date":60,"type":34},"2025-06-19",{"date":62,"type":34},"2025-02-18",{"date":64,"type":22},"2025-12-31",{"name":40,"class":41},1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":66},"100568664","comparison-of-transcatheter-edge-to-edge-repair-using-echo-only-with-echo-combined-with-x-ray-for-mitral-regurgitation-echo-clip-100568664","NCT06684171","Comparison of Transcatheter Edge-to-edge Repair Using Echo Only with Echo Combined with X Ray for Mitral Regurgitation (ECHO-CLIP)","A Randomized Clinical Trial of Transcatheter Edge-to-edge Repair for Mitral Regurgitation Under Fully Echocardiographic Guidance Compared with Under Combined Guidance of Both Echocardiography and Fluoroscopy (ECHO-CLIP Study)","Inclusion Criteria:\n\n\\*Subjects meet either the first or second inclusion criteria in combination with the third and fourth ones were eligible.\n\n1. Symptomatic DMR subjects with MR ≥ 3+ at high surgical risk in terms of STS Predicted Risk of Mortality replacement score ≥ 8 or STS Predicted Risk of Mortality repair score ≥ 6.\\*\n2. FMR subjects with LVESD ≤ 70 mm and MR ≥ 3+, despite administration of GDMT for 30 days.\\*\n3. MV anatomy appropriate for TEER procedure.\n4. Subjects willing to participate in this study and complete the follow-up on schedule after obtaining informed consent.\n\nExclusion Criteria:\n\n1. Myocardial infarction within 12 weeks prior to randomization.\n2. Need for concurrent other cardiac procedures.\n3. Any endovascular intervention or surgery within 30 days prior to randomization.\n4. LVEF \\\u003C 20%.\n5. MV orifice area \\\u003C 4.0 cm2.\n6. Pulmonary artery systolic pressure \\> 70 mmHg, as determined by echocardiogram.\n7. Severe mitral annular calcification.\n8. Unsuitable MV anatomy potentially precluding clip implantation: leaflet calcification or significant leaflet cleft in the grasping zone.\n9. Previous MV surgery or current implanted ventricular assist device or current implanted mechanical prosthetic valve.\n10. Any intracardiac mass, thrombus, or vegetation, as evidenced by echocardiogram.\n11. Active endocarditis or rheumatic heart disease.\n12. History of DVT or PE.\n\nAbbreviations: DMR, degenerative mitral regurgitation; MR, mitral regurgitation; STS, Society of Thoracic Surgeons; FMR, functional mitral regurgitation; LVESD, left ventricular end-systolic diameter; GDMT, guideline-directed medical therapy; TEER, transcatheter edge-to-edge repair; LVEF, left ventricular ejection fraction; MV, mitral valve; DVT, deep venous thrombosis; PE, pulmonary embolism.",{"count":75,"type":22},200,[77],"NA","Mitral regurgitation (MR) is a common valvular heart disease in the elderly population, frequently associated with poor prognosis if not treated. Transcatheter edge-to-edge repair (TEER) has recently emerged as a popular strategy due to minimal invasiveness. What's more, previous studies, such as EVEREST II and COAPT study, have demonstrated its efficacy in high-risk patients with primary or secondary MR. Conventional TEER procedure, however, is performed under combined guidance of both echocardiography and fluoroscopy, which potentially results in high radiation exposure and limits its application. Since 2021 2021, the investigators have changed the procedural methodology by performing TEER under full echocardiographic guidance on accumulated dozens of MR patients successfully. To confirm the efficacy of a fully echo-guided TEER procedure, the investigators conduct the ECHO-CLIP study to compare its outcomes with the conventional TEER procedure, as well as evaluate the outcomes of this novel methodology in special populations with radiation contraindications. ECHO-CLIP study is a prospective, multicenter, open-label, noninferior, randomized controlled trial of TEER by two different methodological strategies in treating severe primary or secondary MR. It is anticipated to enroll a total of 200 patients as well to complete the enrollment before Dec 31, 2025 and the follow-up before Dec 31, 2026. This work will potentially demonstrate the feasibility and efficacy of the fully echo-guided TEER procedure, thereby revolutionizing the TEER methodology and benefiting more patients.",[80],"Mitral Regurgitation",[82,83,84,85,86,87],"mitral regurgitation","transcatheter edge-to-edge repair","ECHO-CLIP","randomized clinical trail","ultrasound","echo","2024-11-08",{"date":90,"type":34},"2024-11-12",{"date":92,"type":34},"2024-03-29",{"date":94,"type":22},"2026-10-31",{"name":40,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":66},"100526568","a-prospective-multicenter-single-arm-study-to-evaluate-a-transcatheter-aortic-valve-system-safety-and-efficacy-for-the-treatment-of-patients-with-severe-aortic-stenosis-100526568","NCT06136429","A Prospective, Multicenter, Single-arm Study to Evaluate a Transcatheter Aortic Valve System Safety and Efficacy for the Treatment of Patients With Severe Aortic Stenosis","A Prospective, Multicenter, Single-arm Target-value Clinical Trial To Evaluate the Transcatheter Aortic Valve System Safety and Efficacy for the Treatment of Patients With Severe Aortic Stenosis","Inclusion Criteria:\n\n1. Age≥ 70 years;\n2. Patients with symptomatic severe aortic stenosis (mean pressure gradient across the aortic valve ≥ 40 mmHg (1 mmHg = 0.133 kPa) on echocardiography, or trans-aortic valve blood flow velocity ≥ 4.0 m\u002Fs, or aortic orifice area ≤ 1.0 cm2, or effective aortic orifice area index ≤0.6 cm2\u002Fm2)\n3. NYHA Grading ≥ Level II;\n4. Life expectancy of more than 1 year after implantation of the prosthetic valve;\n5. Assessed by not less than two cardiothoracic surgeons, documented as a contraindication to surgery, or documented as unsuitable for conventional surgery;\n6. Patients who can understand the purpose of the trial, voluntarily participate in and sign the informed consent form, and are willing to undergo relevant examinations and clinical follow-up.\n\nExclusion Criteria:\n\n1. The imaging data shows that it is anatomically unsuitable for transcatheter aortic valve implantation;\n2. Acute myocardial infarction (defined as Q-wave myocardial infarction, or non-Q-wave myocardial infarction with CK-MB≥ twice normal and\u002For elevated Tn (WHO definition)) occurring within 1 month before valve implantation);\n3. Received any therapeutic traumatic cardiac surgery (other than coronary revascularization) within 1 month before valve implantation;\n4. Implanted prosthetic heart valves at any location, or combined with other valves with severe stenosis or severe regurgitation;\n5. Hemorrhagic constitution or coagulation dysfunction (platelet PLT\\\u003C50×10\\^9\u002FL);\n6. Haemodynamic instability requiring continuous mechanical cardiac assistance;\n7. Severe left ventricular dysfunction, left ventricular ejection fraction LVEF \\\u003C20%;\n8. Echocardiography shows intracardiac thrombosis or vegetation, etc.;\n9. Renal insufficiency decompensation (endogenous creatinine clearance rate\\\u003C20ml\u002Fmin);\n10. Active peptic ulcer or upper gastrointestinal bleeding within 3 months;\n11. Cerebrovascular events (CVAs) within 3 months before valve implantation, excluding transient ischemic attack;\n12. Allergy or contraindication to antiplatelet drugs, anticoagulant drugs, or contrast agents, resulting in the inability to perform preoperative or appropriate intraoperative medication, allergies, or contraindications to polymer materials;\n13. Patients with active infective endocarditis or other active infections;\n14. Concurrent participation in other drug or device studies.\n15. In the opinion of the investigator, it is not suitable for enrollment.","70 Years",{"count":105,"type":22},120,[77],"Trial Title: Prospective, multicenter, single-arm target value clinical trial to evaluate the safety and efficacy of a transcatheter aortic valve system in the treatment of patients with severe aortic stenosis Test device: Transcatheter aortic valve system. Pilot Phase: Clinical Validation of Class III Medical Devices. Study design: prospective, multicenter, single-group target value. Sample size: 120 cases. Intended Use: The Transcatheter Aortic Valve System is indicated for patients with a diagnosis of severe aortic stenosis by the Comprehensive Heart Team.\n\nObjective: This clinical trial is a prospective, multicenter, single-arm study to evaluate the safety and efficacy of the transcatheter aortic valve system in the treatment of patients with severe aortic stenosis.\n\nPrimary endpoint: 12-month postoperative all-cause mortality All-cause deaths include cardiac death and non-cardiac death. Secondary Endpoints: 1. Device success rate 2. Procedural success rate 3. Delivery system performance 4. Retrieval system performance (e.g. using a recycling system) 5. Exchange system performance 6. Valvular function at Immediately postoperative, 7 days\u002Fat discharge, 30 days, 6 months, 12 months, 2-5 years follow-up: valve stenosis, regurgitation, valve function (e.g., opening area, pressure gradient), paravalvular leakage 7. Improvement in quality of life at 30 days, 6 months, 12 months postoperatively 8. Improvement in cardiac function at 7 days\u002Fat discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively\n\nExperimental design:\n\nThis trial is a prospective, multicenter, single-group clinical study with a target value to evaluate the Transcatheter Aortic Valve system Safety and efficacy in the treatment of patients with severe aortic stenosis with 12 months of All-cause mortality after transcatheter aortic valve implantation.\n\nThe mortality rate was the primary study endpoint, and after statistical assumptions and sample size calculations, 120 patients were planned to be enrolled.\n\nPatients were clinically followed immediately after valve implantation, 7 days postoperatively\u002Fat discharge, 30 days, 6 months, 12 months, and 2-5 years postoperatively.\n\nIn this trial, all relevant clinical data were collected, sorted out and statistically analyzed by an independent data management and statistics center and a clinical monitoring institution. All enrolled subjects underwent outpatient follow-up at 30 days, 6 months, and 12 months after surgery, and performed relevant imaging examinations (ultrasound, etc.) and laboratory tests and safety evaluations, and continuous follow-up and cardiac ultrasound examinations were performed annually at 2-5 years to observe the occurrence of adverse events to evaluate the long-term safety of the transcatheter aortic valve system.\n\nThe safety and efficacy of the transcatheter aortic valve system were evaluated with the subject's 12-month postoperative all-cause mortality as the primary endpoint, and the immediate postoperative device success rate, procedural success, retrieval system performance, valve function, cardiac function improvement, quality of life improvement, all-cause mortality in different follow-up periods, major adverse cardiovascular and cerebrovascular events, myocardial infarction, stroke, hemorrhage, acute kidney injury, permanent pacemaker implantation, serious vascular complications, and other TAVR-related complications were taken as the secondary endpoints to assist in evaluating the safety and efficacy of the test product, and to provide a basis for the final official listing and domestic marketing.",[109],"Severe Aortic Stenosis","2023-11-13",{"date":112,"type":34},"2023-11-18",{"date":114,"type":34},"2023-10-18",{"date":116,"type":22},"2029-12-30",{"name":40,"class":41},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":66},"100478320","to-evaluate-the-efficacy-and-safety-of-the-transfemoral-mitral-valve-repair-system-in-the-treatment-of-patients-with-moderately-severe-and-severe-functional-mitral-regurgitationfmr-who-remained-clinically-symptomatic-after-guideline-directed-medical-treatment-100478320","NCT05508438","To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical Treatment","A Prospective, Multicenter, Objective Performance Criteria Clinical Study to Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR)","Inclusion Criteria:\n\n* 1.Age ≥ 18 yrs；\n* 2\\. Symptomatic functional mitral regurgitation (FMR) (≥3+) due to ischemic or non-ischemic cardiomyopathy\n\nNote 1: Functional MR requires the presence of overall or localized left ventricular wall motion abnormalities that are considered to be the primary cause of MR. Despite the eligibility, subjects may not enroll if leaflet prolapse or other evidence of degenerative MR is present.\n\nNote 2: An Eligible transthoracic echocardiography must be obtained at least 30 days after the subject has been stabilized on optimal therapy with Guideline Directed Medical Therapy (GDMT), or at least 30 days under the following conditions after meeting two of the following conditions：Coronary revascularization and\u002For implantation of a cardiac resynchronization therapy device (CRT-P or CRT-D) or reprogramming of the implanted CRT-P or CRT-D resulting in an increase in biventricular pacing (from \\\u003C92% to ≥92%).\n\n* 3\\. Subjects have been adequately treated according to applicable criteria, including treatment for coronary artery disease, left ventricular dysfunction, mitral regurgitation, and heart failure (e.g., with cardiac resynchronization therapy (CRT or CRT-D), coronary revascularization, and\u002For have received stable GDMT, confirmed by the local heart team;\n* 4\\. NYHA functional class II to IV;\n* 5\\. Left ventricular ejection fraction (LVEF) ≥20%;\n* 6\\. Left ventricular end-systolic dimension (LVESD) ≤ 70 mm;\n* 7\\. The subject's mitral valve is anatomically suitable for mitral valve repair;\n* 8\\. Elevated BNP \\>150 pg\u002Fml or corrected NT-proBNP ≥600 pg\u002Fml or heart failure hospitalization within the past 12 months ('corrected' refers to a 4% reduction in the BNP or NT-proBNP cutoff for every increase of 1 kg\u002Fm2 in BMI above a reference BMI of 20 kg\u002Fm2);\n* 9\\. After evaluation, the femoral vein approach is suitable and the puncture through atrial septum is feasible;\n* 10\\. The subjects have been informed of the nature of this study, understand the purpose of the clinical trial, and voluntarily participate in and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Echocardiographic evidence of intracardiac mass, thrombus, or vegetation;\n* 2\\) The presence of other severe heart valve disease requiring surgical intervention.;\n* 3\\) After mitral valve surgery or mitral valve transcatheter surgery;\n* 4)Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis, sarcoidosis, etc.), or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology.;\n* 5\\) Autoimmune myocarditis;\n* 6\\) Heart failure caused by tachyarrhythmia is effective after GDMT treatment;\n* 7\\) Moderate to severe right heart dysfunction or an estimated pulmonary artery systolic pressure (PASP) \\> 70 mmHg assessed by echocardiography;\n* 8\\) History of acute myocardial infarction in the prior 4 weeks or untreated clinically significant coronary artery disease requiring revascularization;\n* 9\\) Any percutaneous cardiac intervention within the 30 days, or any cardiac surgery within the 6 months prior to randomization, or any implant of any Cardiac Resynchronization Therapy (CRT-P) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) or Implantable Cardioverter Defibrillator (ICD) within the last 30days prior to subject registration，or patients who meet the indications of CRT-P and CRT-D but are not implanted;\n* 10\\) In the judgment of the investigator, the subject's femoral vein is unable to accommodate a 22F catheter or has an ipsilateral deep venous thrombosis; or the anatomy is not accessible for transseptal puncture;\n* 11)) Subjects in whom transesophageal echocardiography (TEE) or general anesthesia is contraindicated;\n* 12\\) End-stage heart failure (ACC\u002FAHA stage D), or prior orthotopic heart transplantation, or on the waiting list for heart transplantation.；\n* 13\\) Active endocarditis; Or valvular degeneration caused by active rheumatic heart disease or rheumatic disease (such as poor compliance, perforation, etc)；\n* 14\\) Severe Chronic Obstructive Pulmonary Disease (COPD) (requiring continuous home oxygen therapy or long-term application of steroid hormone medication)；\n* 15\\) Cerebrovascular accident within 30 days prior to randomization or symptomatic severe carotid stenosis (\\> 70% by ultrasound), carotid artery stenting within 30 days.；Cerebrovascular accident (hemorrhagic) within 6 months；\n* 16\\) History of acute peptic ulcer or gastrointestinal bleeding within 3 months；\n* 17)Hemorrhagic or coagulopathic disorders, contraindications to antithrombotic medication；\n* 18\\) Modified Rankin Scale ≥4.；\n* 19\\) The subjects suffer from diseases that may lead to difficulty in evaluating treatment (e.g., cancer, severe metabolic disease, psychosis, etc.)；\n* 20）Pregnant or breastfeeding women, or women who plan to become pregnant within the next 12 months.\n\nNote: Women of childbearing age should take a pregnancy test with a negative result within 14 days prior to registration and use scientifically safe contraception；\n\n* 21\\) Hemodynamic instability defined as systolic pressure \\\u003C 90 mmHg without afterload reduction, cardiogenic shock, or the need for inotropic support or an intra-aortic balloon pump；\n* 22\\) Active infections requiring antibiotic therapy (in the case of temporary illness, antibiotics must be discontinued for at least 14 days before the subject can be enrolled).；\n* 23\\) Currently participating in an investigational drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials；\n* 24\\) In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study.","18 Years",{"count":127,"type":22},140,[77],"To confirm the effectiveness and safety of the transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after guideline-directed medical treatment.",[131],"Mitral Valve Insufficiency",[133,134],"Heart Valve Disease","Cardiovascular Diseases","2022-08-17",{"date":137,"type":34},"2022-08-19",{"date":139,"type":22},"2022-08-30",{"date":141,"type":22},"2027-12-30",{"name":40,"class":41},""]